Chapter 26 Addiction treatment providers' engagements with the Brain Disease Model of Addiction

Debates about the etiology of addiction have a long history and continue to the present day. In contemporary societies, the brain disease model of addiction (BDMA) continues to receive strong support, in particular, from US agencies such as the National Institute on Drug Abuse (NIDA) and the America...

Full description

Saved in:
Bibliographic Details
Main Author: Barnett, Anthony (auth)
Other Authors: Savic, Michael (auth), Pickersgill, Martyn (auth), O'Brien, Kerry (auth), Lubman, Dan I. (auth), Carter, Adrian (auth)
Format: Book Chapter
Published: Taylor & Francis 2022
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02768naaaa2200349uu 4500
001 doab_20_500_12854_75215
005 20220106
020 |a 9781003032762-30 
020 |a 9780367470043 
020 |a 9780367470067 
024 7 |a 10.4324/9781003032762-30  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a MMZ  |2 bicssc 
100 1 |a Barnett, Anthony  |4 auth 
700 1 |a Savic, Michael  |4 auth 
700 1 |a Pickersgill, Martyn  |4 auth 
700 1 |a O'Brien, Kerry  |4 auth 
700 1 |a Lubman, Dan I.  |4 auth 
700 1 |a Carter, Adrian  |4 auth 
245 1 0 |a Chapter 26 Addiction treatment providers' engagements with the Brain Disease Model of Addiction 
260 |b Taylor & Francis  |c 2022 
300 |a 1 electronic resource (13 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Debates about the etiology of addiction have a long history and continue to the present day. In contemporary societies, the brain disease model of addiction (BDMA) continues to receive strong support, in particular, from US agencies such as the National Institute on Drug Abuse (NIDA) and the American Society of Addiction Medicine. Today, there continues to be a significant investment in addiction neuroscience research globally. However, the views of addiction treatment providers about the BDMA, and its clinical impact, are often ignored when debates led by public health researchers and neuroscientists dominate discourse about the neurobiology of addiction. In this chapter, we start by providing a brief history of the biomedicalization of addiction. Moving beyond the question of 'Is addiction a brain disease, or not?', we summarize providers' views about the BDMA and its impact on clinical practice. Drawing on recent critical drug studies scholarship, we critique how a simplistic, linear 'bench to bedside' model of addiction neuroscience translation elides the role treatment providers play in translating neuroscience. Finally, we consider the effects of how the enactment of addiction as a brain disease within policy impacts treatment, and how addiction might be enacted in other ways in future policy frameworks. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by-nc-nd/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ 
546 |a English 
650 7 |a Therapy & therapeutics  |2 bicssc 
653 |a brain disease model; addiction; treatment 
773 1 0 |0 OAPEN Library ID: https://library.oapen.org/handle/20.500.12657/52200  |7 nnaa 
856 4 0 |a www.oapen.org  |u https://library.oapen.org/bitstream/20.500.12657/52200/1/9781003032762_10.4324_9781003032762-30.pdf  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/75215  |7 0  |z DOAB: description of the publication